Trial | NCT00475462  Report issue

Title

The Effectiveness of Metoprolol in the Prevention of Syncope Recurrence in Children and Adolescents

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    metoprolol ...

  • Study Participants

    28
The purpose of this study to evaluate the effectiveness of metoprolol versus conventional treatment in the prevention of syncope recurrence in children and adolescents.
Syncope is often a frustrating clinical problem seen in pediatric patients. Most pediatric syncope is benign, and vasovagal syncope (VVS) is the most common type of syncope seen in children . The diagnosis of VVS is established by history, often confirmed by tilt tests. A wide range of drugs has been proposed for VVS , with β-adrenergic blocking agents being first-line therapy. However, clinical studies have shown conflicting results in terms of therapy effectiveness. β-blockers have been claimed to be effective for 60% to 100% of young patients in many uncontrolled studies but not in most short- and long-term controlled studies . Sheldon et al., in a recent multicenter, double-blinded, placebo-controlled, randomized study of adult patients, reported that metoprolol was not effective in preventing VVS. To our knowledge, no pediatric randomized controlled trials with long-term follow-up have demonstrated the efficacy of β-blockers for the prevention of syncope.
Study Started
Jul 31
2001
Study Completion
Dec 31
2003
Last Update
May 21
2007
Estimate

Drug metoprolol

Drug conventional treatment

Criteria 

Inclusion Criteria:

Children with a history of syncope were included if they had had at least three syncopal episodes per year and had a positive head-up tilt test result.

Exclusion Criteria:

Patients were excluded if they had:

Other causes of syncope;
Cardiovascular and/or systemic disease;
Systolic blood pressure >130 mm Hg or diastolic blood pressure >90 mm Hg； or
History of asthma, impaired liver function, Ⅱ to Ⅲ degrees of atrioventricular block, sinus bradycardia < 40 beats/min, or other contraindications for β-blockers.
No Results Posted